JP2019531084A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019531084A5 JP2019531084A5 JP2019521178A JP2019521178A JP2019531084A5 JP 2019531084 A5 JP2019531084 A5 JP 2019531084A5 JP 2019521178 A JP2019521178 A JP 2019521178A JP 2019521178 A JP2019521178 A JP 2019521178A JP 2019531084 A5 JP2019531084 A5 JP 2019531084A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- chain variable
- variable region
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 44
- 210000004027 cell Anatomy 0.000 claims 40
- 239000000427 antigen Substances 0.000 claims 33
- 108091007433 antigens Proteins 0.000 claims 33
- 102000036639 antigens Human genes 0.000 claims 33
- 230000027455 binding Effects 0.000 claims 30
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 27
- 108020004707 nucleic acids Proteins 0.000 claims 17
- 150000007523 nucleic acids Chemical class 0.000 claims 17
- 102000039446 nucleic acids Human genes 0.000 claims 17
- 206010028980 Neoplasm Diseases 0.000 claims 16
- 108090000765 processed proteins & peptides Proteins 0.000 claims 15
- 102000002029 Claudin Human genes 0.000 claims 13
- 108050009302 Claudin Proteins 0.000 claims 13
- 210000002865 immune cell Anatomy 0.000 claims 12
- 101000685724 Homo sapiens Protein S100-A4 Proteins 0.000 claims 10
- 102100023087 Protein S100-A4 Human genes 0.000 claims 10
- 239000003814 drug Substances 0.000 claims 8
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 5
- 102000002227 Interferon Type I Human genes 0.000 claims 5
- 108010014726 Interferon Type I Proteins 0.000 claims 5
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 5
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 5
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 5
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 5
- 210000001744 T-lymphocyte Anatomy 0.000 claims 5
- 201000004101 esophageal cancer Diseases 0.000 claims 5
- 239000013604 expression vector Substances 0.000 claims 5
- 206010017758 gastric cancer Diseases 0.000 claims 5
- 201000005202 lung cancer Diseases 0.000 claims 5
- 208000020816 lung neoplasm Diseases 0.000 claims 5
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 5
- 238000004519 manufacturing process Methods 0.000 claims 5
- 201000002528 pancreatic cancer Diseases 0.000 claims 5
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 5
- 201000011549 stomach cancer Diseases 0.000 claims 5
- 241000700605 Viruses Species 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 229940075993 receptor modulator Drugs 0.000 claims 3
- 210000004881 tumor cell Anatomy 0.000 claims 3
- 239000013598 vector Substances 0.000 claims 3
- 108010083359 Antigen Receptors Proteins 0.000 claims 2
- 102000006306 Antigen Receptors Human genes 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims 2
- 208000005016 Intestinal Neoplasms Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 2
- 208000008383 Wilms tumor Diseases 0.000 claims 2
- 239000003153 chemical reaction reagent Substances 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 201000010175 gallbladder cancer Diseases 0.000 claims 2
- 201000010536 head and neck cancer Diseases 0.000 claims 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims 2
- 229940127121 immunoconjugate Drugs 0.000 claims 2
- 201000002313 intestinal cancer Diseases 0.000 claims 2
- 230000003834 intracellular effect Effects 0.000 claims 2
- 208000022013 kidney Wilms tumor Diseases 0.000 claims 2
- 201000007270 liver cancer Diseases 0.000 claims 2
- 208000014018 liver neoplasm Diseases 0.000 claims 2
- 210000004698 lymphocyte Anatomy 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 210000000822 natural killer cell Anatomy 0.000 claims 2
- 201000008026 nephroblastoma Diseases 0.000 claims 2
- 230000009871 nonspecific binding Effects 0.000 claims 2
- 206010038038 rectal cancer Diseases 0.000 claims 2
- 201000001275 rectum cancer Diseases 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 claims 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
- 229940125644 antibody drug Drugs 0.000 claims 1
- 230000000890 antigenic effect Effects 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 230000001588 bifunctional effect Effects 0.000 claims 1
- 210000001185 bone marrow Anatomy 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000002458 cell surface marker Substances 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 231100000433 cytotoxic Toxicity 0.000 claims 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims 1
- 230000001472 cytotoxic effect Effects 0.000 claims 1
- 230000003013 cytotoxicity Effects 0.000 claims 1
- 231100000135 cytotoxicity Toxicity 0.000 claims 1
- 229960001904 epirubicin Drugs 0.000 claims 1
- 229960002949 fluorouracil Drugs 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 239000003550 marker Substances 0.000 claims 1
- 238000012986 modification Methods 0.000 claims 1
- 230000004048 modification Effects 0.000 claims 1
- 210000000581 natural killer T-cell Anatomy 0.000 claims 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims 1
- 229960001756 oxaliplatin Drugs 0.000 claims 1
- 210000003289 regulatory T cell Anatomy 0.000 claims 1
- 230000009870 specific binding Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610536449 | 2016-07-08 | ||
| CN201610536449.9 | 2016-07-08 | ||
| PCT/CN2017/082024 WO2017186121A1 (zh) | 2016-04-26 | 2017-04-26 | 一种改善免疫应答细胞功能的方法 |
| CNPCT/CN2017/082024 | 2017-04-26 | ||
| PCT/CN2017/092381 WO2018006882A1 (zh) | 2016-07-08 | 2017-07-10 | 抗密蛋白18a2的抗体及其应用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019531084A JP2019531084A (ja) | 2019-10-31 |
| JP2019531084A5 true JP2019531084A5 (enExample) | 2020-09-03 |
| JP7587921B2 JP7587921B2 (ja) | 2024-11-21 |
Family
ID=60912336
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019521178A Active JP7587921B2 (ja) | 2016-07-08 | 2017-07-10 | 抗クローディンタンパク質１８ａ２の抗体及びその応用 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11111295B2 (enExample) |
| EP (1) | EP3483182B1 (enExample) |
| JP (1) | JP7587921B2 (enExample) |
| KR (1) | KR102723896B1 (enExample) |
| CN (1) | CN109790222B (enExample) |
| AU (1) | AU2017294276B2 (enExample) |
| BR (1) | BR112019000327A8 (enExample) |
| CA (1) | CA3030257A1 (enExample) |
| CL (1) | CL2019000061A1 (enExample) |
| ES (1) | ES2979068T3 (enExample) |
| IL (1) | IL264144B2 (enExample) |
| SG (1) | SG11201900171QA (enExample) |
| WO (1) | WO2018006882A1 (enExample) |
Families Citing this family (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3483182B1 (en) * | 2016-07-08 | 2024-05-08 | CRAGE medical Co., Limited | Antibody for anti-claudin 18a2 and use thereof |
| WO2019149279A1 (zh) | 2018-02-02 | 2019-08-08 | 科济生物医药（上海）有限公司 | 细胞免疫治疗的组合 |
| SG11202007055QA (en) | 2018-03-08 | 2020-09-29 | Phanes Therapeutics Inc | Anti-claudin 18.2 antibodies and uses thereof |
| KR20210013013A (ko) | 2018-03-09 | 2021-02-03 | 카르스젠 테라퓨틱스 리미티드 | 종양 치료 방법 및 조성물 |
| SG11202006217YA (en) * | 2018-03-14 | 2020-07-29 | Beijing Xuanyi Pharmasciences Co Ltd | Anti-claudin 18.2 antibodies |
| CN112074600A (zh) * | 2018-05-03 | 2020-12-11 | 科济生物医药（上海）有限公司 | 免疫效应细胞及其应用 |
| KR20210018838A (ko) | 2018-05-15 | 2021-02-18 | 카르스젠 테라퓨틱스 컴퍼니, 리미티드 | 유전자 조작된 세포 및 응용 |
| AU2019270865B2 (en) * | 2018-05-18 | 2023-03-30 | LaNova Medicines Limited | Anti-claudin 18.2 antibodies and uses thereof |
| KR20210055034A (ko) | 2018-07-24 | 2021-05-14 | 카파 테라퓨틱스 리미티드 | 면역 이펙터 세포를 사용하여 종양을 치료하는 방법 |
| CN118955712A (zh) * | 2018-07-25 | 2024-11-15 | 阿克罗斯生物科学公司 | Cldn 18.2特异性单克隆抗体及其使用方法 |
| CN110857322A (zh) * | 2018-08-22 | 2020-03-03 | 瑞阳(苏州)生物科技有限公司 | 抗人claudin 18.2单克隆抗体及其应用 |
| CA3110593A1 (en) * | 2018-08-27 | 2020-03-05 | Nanjing Sanhome Pharmaceutical Co., Ltd. | Anti-claudin18.2 antibody and use thereof |
| CN109206524B (zh) * | 2018-09-25 | 2022-04-05 | 山东兴瑞生物科技有限公司 | 抗Claudin18A2嵌合抗原受体、其修饰的T细胞及T细胞制备方法和用途 |
| JP2022511394A (ja) * | 2018-09-30 | 2022-01-31 | カファ セラピューティクス リミテッド | Ｃｌｄｎ１８の抗体及び化学療法薬の併用療法 |
| CN113423735B (zh) * | 2018-12-07 | 2024-02-13 | 再鼎医药(上海)有限公司 | 抗-紧密连接蛋白抗体及其用途 |
| EP3892333A4 (en) | 2018-12-07 | 2022-11-30 | CRAGE medical Co., Limited | Tumor combined immunotherapy |
| CN113227146B (zh) | 2018-12-28 | 2024-03-01 | 南京金斯瑞生物科技有限公司 | 密蛋白18.2结合部分和其用途 |
| CN113166246B (zh) * | 2018-12-28 | 2024-10-18 | 四川科伦博泰生物医药股份有限公司 | 一种抗体及其用途 |
| US20220152101A1 (en) * | 2019-01-07 | 2022-05-19 | Carsgen Therapeutics Co., Ltd. | Cellular immunotherapy combination |
| CN114106183B (zh) * | 2019-01-15 | 2023-06-23 | 浙江道尔生物科技有限公司 | 抗cld18a2纳米抗体及其应用 |
| CN109762067B (zh) * | 2019-01-17 | 2020-02-28 | 北京天广实生物技术股份有限公司 | 结合人Claudin 18.2的抗体及其用途 |
| WO2020156554A1 (zh) | 2019-02-01 | 2020-08-06 | 科济生物医药（上海）有限公司 | Tcr融合蛋白及表达tcr融合蛋白的细胞 |
| CN113645996B (zh) * | 2019-02-01 | 2024-04-02 | 新石生物制药有限公司 | 抗claudin 18抗体及其使用方法 |
| KR20210137085A (ko) | 2019-03-05 | 2021-11-17 | 엔카르타, 인크. | Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도 |
| TW202042824A (zh) * | 2019-03-27 | 2020-12-01 | 賓夕法尼亞大學董事會 | Tn-MUC1嵌合抗原受體（CAR）T細胞療法 |
| JP2022527173A (ja) * | 2019-03-29 | 2022-05-31 | フェインズ セラピューティクス，インコーポレーテッド | ヒト化抗クローディン１８．２キメラ抗原受容体及びその使用 |
| US12428478B2 (en) * | 2019-04-01 | 2025-09-30 | Jiangsu Hengrui Medicine Co., Ltd. | Anti-Claudin 18.2 antibody and application thereof |
| US20220372112A1 (en) * | 2019-04-19 | 2022-11-24 | Keymed Biosciences Co., Ltd. | Tumor therapeutic agent and use thereof |
| CA3138414A1 (en) | 2019-05-16 | 2020-11-19 | Qilu Pharmaceutical Co., Ltd. | Antibodyagainst claudin 18a2 and use thereof |
| CN111978402B (zh) * | 2019-05-24 | 2022-06-28 | 三优生物医药(上海)有限公司 | 新型cldn18.2结合分子 |
| JP7600218B2 (ja) * | 2019-05-24 | 2024-12-16 | サンヨウ バイオファーマシューティカルズ カンパニー リミテッド | 新規なｃｌｄｎ１８．２結合分子 |
| CN114127109B (zh) * | 2019-05-30 | 2022-06-21 | 山东博安生物技术股份有限公司 | 靶向Claudin18.2的抗体或嵌合抗原受体 |
| EP3999548A4 (en) * | 2019-07-17 | 2023-08-16 | The Regents of the University of California | CLAUDIN18 ANTIBODIES AND METHODS OF TREATMENT OF CANCER |
| MY207446A (en) * | 2019-08-12 | 2025-02-27 | Abl Bio Inc | Anti-claudin 18.2 and anti-4-1bb bispecific antibodies and uses thereof |
| CN112574307B (zh) | 2019-09-29 | 2023-11-28 | 迈威(上海)生物科技股份有限公司 | 抗人Claudin18.2抗体及其应用 |
| CN114269389B (zh) * | 2019-11-05 | 2022-12-27 | 礼新医药科技(上海)有限公司 | 靶向紧密连接蛋白18.2的抗体药物偶联物 |
| US20230000918A1 (en) * | 2019-11-29 | 2023-01-05 | Suzhou Nova Therapeutics Co. Ltd | Chimeric antigen receptors, compositions and applications thereof |
| CN114901696B (zh) | 2019-12-06 | 2025-08-05 | 斯迪安生物技术公司 | 人源化cldn18.2抗体 |
| US20240034783A1 (en) | 2019-12-23 | 2024-02-01 | Sotio Biotech A.S. | Tumor-specific claudin 18.2 antibodies |
| US20230061005A1 (en) * | 2020-01-03 | 2023-03-02 | Crage Medical Co., Limited | Anti-claudin 18.2 antibody and use thereof |
| WO2021160155A1 (zh) * | 2020-02-10 | 2021-08-19 | 上海诗健生物科技有限公司 | 密蛋白18.2的抗体及其用途 |
| WO2021173307A1 (en) * | 2020-02-25 | 2021-09-02 | Gensun Biopharma Inc. | Trispecific t cell engagers |
| CN115715202B (zh) * | 2020-05-15 | 2025-11-04 | 四川科伦博泰生物医药股份有限公司 | 抗体药物缀合物及其制备方法和用途 |
| CA3178855A1 (en) * | 2020-06-19 | 2021-12-23 | Innovent Biologics (Suzhou) Co., Ltd. | Anti-claudin18.2 antibody and use thereof |
| CN111704669B (zh) * | 2020-07-13 | 2022-05-13 | 北京凯因科技股份有限公司 | 一种用于治疗晚期胃癌的抗cldn18全人源化抗体 |
| CN111808194B (zh) * | 2020-07-13 | 2021-04-20 | 北京凯因科技股份有限公司 | 一种结合密蛋白的用于治疗癌症的人源化抗体 |
| CN111961135B (zh) * | 2020-07-13 | 2022-08-16 | 北京亦庄国际蛋白药物技术有限公司 | 一种用于预防或治疗癌症的抗体 |
| WO2022011531A1 (zh) * | 2020-07-14 | 2022-01-20 | 浙江道尔生物科技有限公司 | 一种抗cld18a2的单域抗体 |
| WO2022028623A1 (zh) | 2020-08-07 | 2022-02-10 | 佧珐药业有限公司 | 工程化改造的细胞以及工程化改造细胞的方法 |
| JP2023543493A (ja) * | 2020-09-30 | 2023-10-16 | ナンジン、ジェンスクリプト、バイオテック、カンパニー、リミテッド | ヒトクローディン１８．２を標的とする抗体及びその使用 |
| WO2022122709A1 (en) * | 2020-12-07 | 2022-06-16 | Sotio Biotech A.S. | Antibody-drug conjugates based on humanized cldn18.2 antibodies |
| US12404315B2 (en) | 2020-12-21 | 2025-09-02 | Allogene Therapeutics, Inc. | Protease-activating CD45-gate CAR |
| WO2022136642A1 (en) | 2020-12-23 | 2022-06-30 | Sotio Biotech A.S. | Tumor-specific claudin 18.2 antibody-drug conjugates |
| JP2024505075A (ja) | 2021-01-29 | 2024-02-02 | アロジーン セラピューティクス，インコーポレイテッド | 同種細胞産物のＴ細胞認識を軽減するための、ＴＡＰ２、ＮＬＲＣ５、β２ｍ、ＴＲＡＣ、ＲＦＸ５、ＲＦＸＡＰ及びＲＦＸＡＮＫのうち１つ以上のノックダウン又はノックアウト |
| EP4321533A4 (en) * | 2021-04-08 | 2025-05-07 | Crage Medical Co., Limited | USE OF CELLULAR IMMUNOTHERAPY |
| CN117480247A (zh) * | 2021-04-15 | 2024-01-30 | 恺兴生命科技(上海)有限公司 | 嵌合t细胞受体及其应用 |
| US20250269028A1 (en) | 2021-06-29 | 2025-08-28 | Carsgen Therapeutics Co., Ltd | Chimeric polypeptide for regulating cell physiological activity |
| CN114751984B (zh) * | 2021-09-03 | 2023-02-14 | 深圳市先康达生命科学有限公司 | 靶向人Claudin18.2蛋白的单克隆抗体及其应用 |
| US20240409629A1 (en) * | 2021-11-05 | 2024-12-12 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Anti-cldn18.2 antibody and use thereof |
| CN119677781A (zh) * | 2022-05-06 | 2025-03-21 | 上海先博生物科技有限公司 | 靶向cldn18.2的嵌合抗原t细胞受体及其应用 |
| CN119654342B (zh) * | 2022-07-28 | 2025-07-18 | 乐普创一生物科技（上海）有限公司 | 抗MerTK抗体及其用途 |
| JP2025525779A (ja) | 2022-07-29 | 2025-08-07 | アロジーン セラピューティクス，インコーポレイテッド | 免疫細胞の認識を低減させるために遺伝子発現が低下した、操作された細胞 |
| TW202434307A (zh) | 2023-01-18 | 2024-09-01 | 大陸商泰勵生物科技（上海）有限公司 | 抗體偶聯藥物及其用途 |
| WO2025026347A1 (en) * | 2023-07-31 | 2025-02-06 | Nanjing Legend Biotech Co., Ltd. | Chimeric cytokine receptors and methods of use thereof |
| WO2025076127A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| WO2025096560A1 (en) | 2023-10-30 | 2025-05-08 | Allogene Therapeutics, Inc. | Engineered cells |
| CN117430708B (zh) * | 2023-12-21 | 2024-04-09 | 苏州近岸蛋白质科技股份有限公司 | 一种抗Claudin18.2抗体 |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
| CN120005046B (zh) * | 2025-04-18 | 2025-09-02 | 深锐(天津)生物医学有限公司 | 双靶点嵌合抗原受体联合pd-1与il-21融合蛋白 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1790664A1 (en) | 2005-11-24 | 2007-05-30 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against claudin-18 for treatment of cancer |
| WO2013167153A1 (en) | 2012-05-09 | 2013-11-14 | Ganymed Pharmaceuticals Ag | Antibodies useful in cancer diagnosis |
| WO2014127785A1 (en) * | 2013-02-20 | 2014-08-28 | Ganymed Pharmaceuticals Ag | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer |
| WO2014146672A1 (en) | 2013-03-18 | 2014-09-25 | Ganymed Pharmaceuticals Ag | Therapy involving antibodies against claudin 18.2 for treatment of cancer |
| CN105315375B (zh) * | 2014-07-17 | 2021-04-23 | 恺兴生命科技(上海)有限公司 | 靶向cld18a2的t淋巴细胞及其制备方法和应用 |
| CN105331585A (zh) * | 2015-11-13 | 2016-02-17 | 科济生物医药（上海）有限公司 | 携带pd-l1阻断剂的嵌合抗原受体修饰的免疫效应细胞 |
| AU2016364853A1 (en) | 2015-12-04 | 2018-06-21 | Abbvie Stemcentrx Llc | Novel anti-claudin antibodies and methods of use |
| CN118146379B (zh) * | 2016-04-26 | 2025-09-09 | 恺兴生命科技(上海)有限公司 | 一种改善免疫应答细胞功能的方法 |
| EP3483182B1 (en) * | 2016-07-08 | 2024-05-08 | CRAGE medical Co., Limited | Antibody for anti-claudin 18a2 and use thereof |
| KR20210013013A (ko) * | 2018-03-09 | 2021-02-03 | 카르스젠 테라퓨틱스 리미티드 | 종양 치료 방법 및 조성물 |
| JP2022511394A (ja) * | 2018-09-30 | 2022-01-31 | カファ セラピューティクス リミテッド | Ｃｌｄｎ１８の抗体及び化学療法薬の併用療法 |
| US20220152101A1 (en) * | 2019-01-07 | 2022-05-19 | Carsgen Therapeutics Co., Ltd. | Cellular immunotherapy combination |
| US20230272341A1 (en) * | 2020-08-10 | 2023-08-31 | Crage Medical Co., Limited | Multifunctional immune effector cell and use thereof |
-
2017
- 2017-07-10 EP EP17823694.9A patent/EP3483182B1/en active Active
- 2017-07-10 ES ES17823694T patent/ES2979068T3/es active Active
- 2017-07-10 IL IL264144A patent/IL264144B2/en unknown
- 2017-07-10 CA CA3030257A patent/CA3030257A1/en active Pending
- 2017-07-10 BR BR112019000327A patent/BR112019000327A8/pt active Search and Examination
- 2017-07-10 KR KR1020197003874A patent/KR102723896B1/ko active Active
- 2017-07-10 WO PCT/CN2017/092381 patent/WO2018006882A1/zh not_active Ceased
- 2017-07-10 AU AU2017294276A patent/AU2017294276B2/en active Active
- 2017-07-10 US US16/316,331 patent/US11111295B2/en active Active
- 2017-07-10 CN CN201780042611.4A patent/CN109790222B/zh active Active
- 2017-07-10 JP JP2019521178A patent/JP7587921B2/ja active Active
- 2017-07-10 SG SG11201900171QA patent/SG11201900171QA/en unknown
-
2019
- 2019-01-08 CL CL2019000061A patent/CL2019000061A1/es unknown
-
2021
- 2021-08-05 US US17/395,223 patent/US20220185880A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019531084A5 (enExample) | ||
| AU2016281641B2 (en) | Novel PD-1 immune modulating agents | |
| JP2020510422A5 (enExample) | ||
| JP2017519759A5 (enExample) | ||
| JP2022093564A5 (enExample) | ||
| JP2020501531A5 (enExample) | ||
| JP2017535257A5 (enExample) | ||
| JP2019532625A5 (enExample) | ||
| RU2014101669A (ru) | Агенты, связывающие белки r-спондины (rspo), и способы их применения | |
| JP2018527919A5 (enExample) | ||
| JP2013527762A5 (enExample) | ||
| JP2018532383A5 (enExample) | ||
| JP2018529327A5 (enExample) | ||
| JP2018506961A5 (enExample) | ||
| JP2013506428A5 (enExample) | ||
| JP2013527761A5 (enExample) | ||
| JP2014522850A5 (enExample) | ||
| HRP20120701T1 (hr) | Humana monoklonska protutijela protiv fukozil-gm1 i postupci za uporabu antifukozil-gm1 | |
| JP2010535713A5 (enExample) | ||
| JP2017526339A5 (enExample) | ||
| JP2019512207A5 (enExample) | ||
| JP2013519364A5 (enExample) | ||
| RU2018122629A (ru) | Антитела против 5t4 и конъюгаты антитело-лекарственное средство | |
| JP2020534012A5 (enExample) | ||
| JP2017521054A5 (enExample) |